Aug. 27, 2026 /PRNewswire/ — AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively “AusperBio” or the “Company”), a near-commercial biopharmaceutical company focused on developing targeted oligonucleotide therapeutics for the treatment of chronic hepatitis B (CHB) and other diseases, today announced the closing of its $120 million Series C financing
